Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters Solutions Now Shipping with UNIFI 1.6

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
UNIFI 1.6 is industry’s first multi-user, server-based technology for management of analytical LC, LC/MS, and LC/MS/MS data.

Waters Corporation is now shipping UNIFI® Scientific Information System, release version 1.6, for the Waters® Biopharmaceutical Platform Solution, Regulated Bioanalysis Platform Solution, Screening Platform Solution, Pesticide Screening Application Solution and Metabolite Identification Application Solution.

UNIFI 1.6 features improved software performance, default and customizable workflows capabilities, and multi-user server-based connectivity.

“With industry-leading core technology positions in separations, detection, chemistries, and informatics, Waters is uniquely positioned to develop systems that optimize technology performance for dedicated application areas,” said Dr. Rohit Khanna, Vice President of Informatics and Worldwide Marketing for the Waters Division.

Dr. Khanna continued, “With each release of UNIFI, we are working and collaborating with customers to guide development of future platform and application solutions. The expansion of UNIFI-based solutions is an evolutionary process that is proving successful for our customers.”

With version 1.6, UNIFI significantly expands its available laboratory footprint from a single workstation to support multi-user, server-based workgroups for the capture, storage, and management of analytical LC, LC/MS, and LC/MS/MS data across applications.

Additionally with this release, UNIFI advances its ability to manage and store exponentially larger dataset files with improved robustness, performance, and processing speed.

“This is major step forward towards Waters’ vision for UNIFI as an enterprise-wide Scientific Information System,” continued Dr. Khanna.

“UNIFI’s workgroup configuration is designed to support multiple scientists …within a common software environment. From acquisition to data interpretation to reporting, UNIFI comprehensively captures scientific workflow. UNIFI offers laboratory-dependent organizations improved abilities to unite the knowledge and improve productivity of their researchers.”

Biopharmaceutical Platform Solution with UNIFI™ is a targeted total solution for developers of biotherapeutics and biosimilars. The system solution consists of the ACQUITY UltraPerformance LC® (UPLC®) H-Class, the Xevo® G2-S QT of mass spectrometer, Waters’ application-tested bioseparation column chemistries, and analytical standards.

Regulated Bioanalysis Platform Solution with UNIFI is an LC/MS/MS system for drug metabolism and pharmacokinetic (DMPK) organizations and CROs that combines the latest in sample preparation, UPLC and chemistries, and tandem quadrupole mass spectrometry.

Screening Platform Solution with UNIFI is the first and only comprehensive screening solution to target, identify, quantify and review based on a streamlined analytical workflow that enables more accurate results across a variety of applications. The holistically designed Platform Solution consists of the ACQUITY UPLC I-Class, the Xevo G2-S QT of mass spectrometer, Waters Analytical Standards & Reagents and Waters Chemistries.

Pesticide Screening Application Solution with UNIFI delivers the ease-of-use, sensitivity, stability, reproducibility, and throughput scientists need to successfully and profitably perform pesticide residue screening in a manner compliant with regulatory requirements today and in the future.

Metabolite Identification Application Solution with UNIFI is the world’s most comprehensive metabolite identification system assisting the DMPK scientist in identifying and characterizing metabolites in both discovery and development environments. Chemically intelligent yet flexible workflows are at the core of UNIFI’s design. The workflow approach integrates both quantitative and qualitative datasets and workflows into a single analysis.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters and Ireland's NIBRT Partner on Training and Research
The partnership will increase large molecule characterization capacity and knowledge, helping to deliver new, more effective therapeutic options.
Thursday, September 27, 2012
Waters Selects Prof. Pauline Rudd for Center of Innovation Program Honors
Waters-NIBRT partnership advances biopharmaceutical research, characterization and training.
Friday, April 06, 2012
Waters, Ireland’s NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry
Will increase large molecule characterization capacity and knowledge, help deliver new, more effective therapeutic options.
Tuesday, April 03, 2012
Waters and Tecan Sign Agreement for Clinical Assay Platform
The agreement will address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays.
Wednesday, January 18, 2012
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!